Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms.

Kabir ZD, Martínez-Rivera A, Rajadhyaksha AM.

Neurotherapeutics. 2017 Jul;14(3):588-613. doi: 10.1007/s13311-017-0532-0. Review.

PMID:
28497380
2.

CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease.

Bhat S, Dao DT, Terrillion CE, Arad M, Smith RJ, Soldatov NM, Gould TD.

Prog Neurobiol. 2012 Oct;99(1):1-14. doi: 10.1016/j.pneurobio.2012.06.001. Epub 2012 Jun 15. Review.

3.

P/Q-type calcium channel modulators.

Nimmrich V, Gross G.

Br J Pharmacol. 2012 Oct;167(4):741-59. doi: 10.1111/j.1476-5381.2012.02069.x. Review.

4.

Genetic variation in CACNA1C affects brain circuitries related to mental illness.

Bigos KL, Mattay VS, Callicott JH, Straub RE, Vakkalanka R, Kolachana B, Hyde TM, Lipska BK, Kleinman JE, Weinberger DR.

Arch Gen Psychiatry. 2010 Sep;67(9):939-45. doi: 10.1001/archgenpsychiatry.2010.96.

5.

Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms.

Mallinger AG, Thase ME, Haskett R, Buttenfield J, Luckenbaugh DA, Frank E, Kupfer DJ, Manji HK.

Bipolar Disord. 2008 Dec;10(8):856-66. doi: 10.1111/j.1399-5618.2008.00636.x.

6.

Promising avenues of therapeutics for bipolar illness.

Post RM.

Dialogues Clin Neurosci. 2008;10(2):193-201. Review.

7.

Neuropsychiatric consequences of cardiovascular medications.

Huffman JC, Stern TA.

Dialogues Clin Neurosci. 2007;9(1):29-45. Review.

Supplemental Content

Support Center